Insulin Delivery Devices Market 2019 Synopsis and Highlights: Key Findings with Worldwide Top Companies Novo Nordisk A/S, Becton, Dickinson and Company, Sanofi S.A., F. Hoffmann-La Roche, Ltd., Eli Lilly

Manufacturers in the market are focusing on developing advanced insulin pumps that will save time in administration. For instance, in 2016, Medtronic received FDA approval for the launch of MiniMed 630G in the U.S. The system features a new insulin pump hardware platform and new user-friendly insulin pump design, and SmartGuard technology, which mimics the function of healthy pancreas to provide advanced protection.

Patients in developed economies such as the U.S. and Europe are early adopters of novel technologies such as insulin pumps and artificial pancreas devices. Emerging economies are also expected to witness increasing demand for conventional insulin delivery devices such as insulin pens, due to their lower cost. However, risks and complication associated with the delivery of insulin and packaging of insulin are factors restraining demand for insulin delivery devices. In July 2017, Novo Nordisk recalled certain insulin cartridge holders used in connection with the company’s NovoPen Echo-brand insulin delivery devices as cartridge holders might crack or break if exposed to certain chemicals such as cleaning agents result in a patient receiving a reduced dose of insulin, which could potentially lead to high blood sugar.

Access PDF Template Copy of this Report at:
https://www.coherentmarketinsights.com/insight/request-sample/1352

Key takeaways of the Insulin Delivery Devices Market:

The global insulin delivery devices market is expected to expand at a CAGR of 11.3% over the forecast period as there exists a huge market especially in Asia Pacific, Latin America, Middle East, and Africa owing to increasing diabetic patient pool in these regions.

Among product types, insulin pen devices is expected be the dominant segment in the market, as it is preferred owing to these features such as easy to use and carry

Among distribution channel, hospital pharmacies segment accounted for the largest share in the insulin delivery devices market. Favorable reimbursement scenario and increasing number of hospital pharmacies especially in the developing countries expected to fuel the growth of this segment during the forecast period.

Some of the major players involved in global insulin delivery devices market are Novo Nordisk A/S, Becton, Dickinson and Company, Sanofi S.A., F. Hoffmann-La Roche, Ltd., Eli Lilly and Company, Medtronic, Plc, Ypsomed Holding AG, Animas Corporation, and Insulet Corporation.

The Global Insulin Delivery Devices Market, by Product Type (Insulin Syringes, Insulin Pens, Insulin Pumps, Insulin Jet Injectors), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) was valued at US$ 11,326.9 million in 2017 and is projected to exhibit a CAGR of 11.3% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Advancements in technology in insulin delivery devices by key players, and rising prevalence of diabetes are expected to be major factors driving growth of the global insulin delivery devices market over the forecast period.

Insulin plays a vital role in the treatment of diabetes as it aids in controlling the blood glucose level in diabetes patients. Diabetes is considered to be one of the most prevalent disease in the world, as stated by the World Health Organization and resulted in 1.6 million deaths in 2015, globally. There are few devices that can be used to deliver insulin, including syringes, insulin pens, jet injectors, and insulin pumps. After getting infused or injected into the diabetic patient’s body, insulin helps to get glucose from the bloodstream into the fat cells or muscle. Increasing adaption of these devices coupled with rising number of patients with diabetes is expected to act as a major factor to boost growth of insulin delivery devices market. In addition to this, manufacturers are also focusing on investing in new technologies, which can address the current shortcomings of these drug delivery systems such as durability, painful procedure and cost, thus meeting the unmet needs of diabetic patients.

Get Customized Report in your Inbox within 24 hours @
https://www.coherentmarketinsights.com/insight/request-customization/1352

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.